Lymphoproliferative Disorders

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-11-24
EMA Authorised: Ebvallo (tabelecleucel) — Pierre Fabre Medicament
The EMA authorised Ebvallo (tabelecleucel) for lymphoproliferative disorders; the therapy is developed by Pierre Fabre Medicament and design…